Statins improve outcomes of nonsurgical curative treatments in hepatocellular carcinoma patients

Li Li Wu, Mao Chih Hsieh, Jyh Ming Chow, Shing Hwa Liu, Chia Lun Chang, Szu Yuan Wu

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Statins are associated with a reduced risk of hepatocellular carcinoma (HCC) and have the potential to be an adjuvant agent for HCC. In this study, we examined whether statin use is associated with additional benefits among patients who received curative treatments (CTs) such as surgery, percutaneous ethanol injection (PEI), and radiofrequency ablation (RFA). We conducted a cohort study using the Taiwan National Health Insurance Research Data linked to the Taiwan Cancer Registry in 2001 to 2012. The patient cohort consisted of those who received different treatments, and we compared patients who received statins with those who did not. Statin users were defined as patients who received >28 cumulative defined daily doses after their HCC diagnosis. We used a time-dependent Cox proportional method to model the time from the HCC diagnosis to any death and HCC death between men who received statins and those who did not after adjusting for confounders. Data on statin prescriptions were collected every 6 months to define the user status. In total, 18,892 patients were included, and the mean follow-up duration was 1.74 years. The adjusted hazard ratio (aHR) of allcause deaths increased in HCC patients who received RFA/PEI compared to those who received surgery (P<0.0001 and P<0.05, with aHRs of 1.81 and 1.16, respectively, for hepatitis B virus [HBV] or non-HBV HCC). However, with the addition of statin use to RFA or PEI, the overall survival was statistically equal. Surgical resection is still superior over other therapies. If HCC patients cannot meet the criteria for surgery, the addition of statin use to RFA or PEI might improve HCC survival.

Original languageEnglish
Article numbere4639
JournalMedicine (United States)
Volume95
Issue number36
DOIs
Publication statusPublished - 2016

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hepatocellular Carcinoma
Ethanol
Injections
Therapeutics
Taiwan
Cercopithecine Herpesvirus 1
Survival
National Health Programs
Hepatitis B virus
Prescriptions
Registries
Cohort Studies

Keywords

  • Adjuvant therapy
  • Curative treatment
  • HCC
  • PEI
  • RFA
  • Statins
  • Surgery

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Statins improve outcomes of nonsurgical curative treatments in hepatocellular carcinoma patients. / Wu, Li Li; Hsieh, Mao Chih; Chow, Jyh Ming; Liu, Shing Hwa; Chang, Chia Lun; Wu, Szu Yuan.

In: Medicine (United States), Vol. 95, No. 36, e4639, 2016.

Research output: Contribution to journalArticle

@article{86555bc02b7f42b9a5d19b46fa696c6f,
title = "Statins improve outcomes of nonsurgical curative treatments in hepatocellular carcinoma patients",
abstract = "Statins are associated with a reduced risk of hepatocellular carcinoma (HCC) and have the potential to be an adjuvant agent for HCC. In this study, we examined whether statin use is associated with additional benefits among patients who received curative treatments (CTs) such as surgery, percutaneous ethanol injection (PEI), and radiofrequency ablation (RFA). We conducted a cohort study using the Taiwan National Health Insurance Research Data linked to the Taiwan Cancer Registry in 2001 to 2012. The patient cohort consisted of those who received different treatments, and we compared patients who received statins with those who did not. Statin users were defined as patients who received >28 cumulative defined daily doses after their HCC diagnosis. We used a time-dependent Cox proportional method to model the time from the HCC diagnosis to any death and HCC death between men who received statins and those who did not after adjusting for confounders. Data on statin prescriptions were collected every 6 months to define the user status. In total, 18,892 patients were included, and the mean follow-up duration was 1.74 years. The adjusted hazard ratio (aHR) of allcause deaths increased in HCC patients who received RFA/PEI compared to those who received surgery (P<0.0001 and P<0.05, with aHRs of 1.81 and 1.16, respectively, for hepatitis B virus [HBV] or non-HBV HCC). However, with the addition of statin use to RFA or PEI, the overall survival was statistically equal. Surgical resection is still superior over other therapies. If HCC patients cannot meet the criteria for surgery, the addition of statin use to RFA or PEI might improve HCC survival.",
keywords = "Adjuvant therapy, Curative treatment, HCC, PEI, RFA, Statins, Surgery",
author = "Wu, {Li Li} and Hsieh, {Mao Chih} and Chow, {Jyh Ming} and Liu, {Shing Hwa} and Chang, {Chia Lun} and Wu, {Szu Yuan}",
year = "2016",
doi = "10.1097/MD.0000000000004639",
language = "English",
volume = "95",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "36",

}

TY - JOUR

T1 - Statins improve outcomes of nonsurgical curative treatments in hepatocellular carcinoma patients

AU - Wu, Li Li

AU - Hsieh, Mao Chih

AU - Chow, Jyh Ming

AU - Liu, Shing Hwa

AU - Chang, Chia Lun

AU - Wu, Szu Yuan

PY - 2016

Y1 - 2016

N2 - Statins are associated with a reduced risk of hepatocellular carcinoma (HCC) and have the potential to be an adjuvant agent for HCC. In this study, we examined whether statin use is associated with additional benefits among patients who received curative treatments (CTs) such as surgery, percutaneous ethanol injection (PEI), and radiofrequency ablation (RFA). We conducted a cohort study using the Taiwan National Health Insurance Research Data linked to the Taiwan Cancer Registry in 2001 to 2012. The patient cohort consisted of those who received different treatments, and we compared patients who received statins with those who did not. Statin users were defined as patients who received >28 cumulative defined daily doses after their HCC diagnosis. We used a time-dependent Cox proportional method to model the time from the HCC diagnosis to any death and HCC death between men who received statins and those who did not after adjusting for confounders. Data on statin prescriptions were collected every 6 months to define the user status. In total, 18,892 patients were included, and the mean follow-up duration was 1.74 years. The adjusted hazard ratio (aHR) of allcause deaths increased in HCC patients who received RFA/PEI compared to those who received surgery (P<0.0001 and P<0.05, with aHRs of 1.81 and 1.16, respectively, for hepatitis B virus [HBV] or non-HBV HCC). However, with the addition of statin use to RFA or PEI, the overall survival was statistically equal. Surgical resection is still superior over other therapies. If HCC patients cannot meet the criteria for surgery, the addition of statin use to RFA or PEI might improve HCC survival.

AB - Statins are associated with a reduced risk of hepatocellular carcinoma (HCC) and have the potential to be an adjuvant agent for HCC. In this study, we examined whether statin use is associated with additional benefits among patients who received curative treatments (CTs) such as surgery, percutaneous ethanol injection (PEI), and radiofrequency ablation (RFA). We conducted a cohort study using the Taiwan National Health Insurance Research Data linked to the Taiwan Cancer Registry in 2001 to 2012. The patient cohort consisted of those who received different treatments, and we compared patients who received statins with those who did not. Statin users were defined as patients who received >28 cumulative defined daily doses after their HCC diagnosis. We used a time-dependent Cox proportional method to model the time from the HCC diagnosis to any death and HCC death between men who received statins and those who did not after adjusting for confounders. Data on statin prescriptions were collected every 6 months to define the user status. In total, 18,892 patients were included, and the mean follow-up duration was 1.74 years. The adjusted hazard ratio (aHR) of allcause deaths increased in HCC patients who received RFA/PEI compared to those who received surgery (P<0.0001 and P<0.05, with aHRs of 1.81 and 1.16, respectively, for hepatitis B virus [HBV] or non-HBV HCC). However, with the addition of statin use to RFA or PEI, the overall survival was statistically equal. Surgical resection is still superior over other therapies. If HCC patients cannot meet the criteria for surgery, the addition of statin use to RFA or PEI might improve HCC survival.

KW - Adjuvant therapy

KW - Curative treatment

KW - HCC

KW - PEI

KW - RFA

KW - Statins

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84988354894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988354894&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000004639

DO - 10.1097/MD.0000000000004639

M3 - Article

C2 - 27603355

AN - SCOPUS:84988354894

VL - 95

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 36

M1 - e4639

ER -